SIBN / SI-BONE: Multiple Inflection Points On The Horizon In FY 2023

SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis more_horizontal

SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis more_horizontal

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year. more_horizontal

SI-BONE, Inc. presents compelling long-term value with robust growth in unit economics, high gross profits, and attractive valuation upside. Q2 FY'23 more_horizontal

SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis more_horizontal

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, FP&A and I more_horizontal

SANTA CLARA, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis more_horizontal